Author: United States. Congress. House. Committee on the Judiciary. Subcommittee on CrimePublisher:
ISBN:
Category : Drugs
Languages : en
Pages : 474
Book Description
Diversion of Prescription Drugs to Illegal Channels and Dangerous Drug Diversion Control Act
Author: United States. Congress. House. Committee on the Judiciary. Subcommittee on CrimePublisher:
ISBN:
Category : Drugs
Languages : en
Pages : 474
Book Description
Diversion of Prescription Drugs to Illegal Channels and Dangerous Drug Diversion Control Act
Author: United States. Congress. House. Committee on the Judiciary. Subcommittee on CrimePublisher:
ISBN:
Category : Drugs
Languages : en
Pages : 466
Book Description
Diversion of Prescription Drugs to Illegal Channels and Dangerous Drug Diversion Control Act
Author: United States. Congress. House. Committee on the Judiciary. Subcommittee on CrimePublisher:
ISBN:
Category : Drugs
Languages : en
Pages : 480
Book Description
Federal Regulation of Methadone Treatment
Author: Committee on Federal Regulation of Methadone TreatmentPublisher: National Academies Press
ISBN: 0309598621
Category : Medical
Languages : en
Pages : 223
Book Description
For nearly three decades, methadone hydrochloride has been the primary means of treating opiate addiction. Today, about 115,000 people receive such treatment, and thousands more have benefited from it in the past. Even though methadone's effectiveness has been well established, its use remains controversial, a fact reflected by the extensive regulation of its manufacturing, labeling, distribution, and use. The Food and Drug Administration regulates the safety and effectiveness of methadone, as it does for all drugs, and the Drug Enforcement Administration regulates it as a controlled substance. However, methadone is also subjected to a unique additional tier of regulation that prescribes how and under what circumstances it may be used to treat opiate addiction. Federal Regulation of Methadone Treatment examines current Department of Health and Human Services standards for narcotic addiction treatment and the regulation of methadone treatment programs pursuant to those standards. The book includes an evaluation of the effect of federal regulations on the provision of methadone treatment services and an exploration of options for modifying the regulations to allow optimal clinical practice. The volume also includes an assessment of alternatives to the existing regulations.
Psychoactive Drug Diversion
Author: United States. Congress. House. Select Committee on Narcotics Abuse and ControlPublisher:
ISBN:
Category : Drugs
Languages : en
Pages : 20
Book Description
Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care
Author: Committee Report on CSA Laws
Author: Controlled Substances
Author: United States. General Accounting OfficePublisher:
ISBN:
Category : Drug abuse
Languages : en
Pages : 36
Book Description
In response to a congressional request, GAO assessed the possibility of using Medicaid data to identify health care providers who may be diverting prescription drugs for illegal purposes. GAO found that states should use data contained in the Medicaid Management Information System (MMIS) to identify health care providers who may be illegally diverting controlled substances, since: (1) states' MMIS often comprise the largest databases on the prescription and dispensing of controlled substances; (2) Medicaid laws allow disclosure of the data; and (3) it would enable law enforcement officials and licensing and regulatory agencies to identify sources of drug diversion.
Pain Management and the Opioid Epidemic
Author: National Academies of Sciences, Engineering, and MedicinePublisher: National Academies Press
ISBN: 0309459575
Category : Medical
Languages : en
Pages : 483
Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Prescription Drug Monitoring
Author: United States. General Accounting OfficePublisher:
ISBN:
Category : Drug utilization
Languages : en
Pages : 20
Book Description